1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial
(
- Contribution to journal › Article
- 2006
-
Mark
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis
(
- Contribution to journal › Article
-
Mark
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective
(
- Contribution to journal › Article
- 2005
-
Mark
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
(
- Contribution to journal › Article
-
Mark
Body mass index as a predictor of fracture risk: A meta-analysis
(
- Contribution to journal › Article
-
Mark
The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach
(
- Contribution to journal › Article
- 2004
-
Mark
Osteoporosis and the global competition for health care resources
(
- Contribution to journal › Article
-
Mark
Health-related quality of life and radiographic vertebral fracture
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
(
- Contribution to journal › Article